To evaluate IMB-1018972 on cardiac energetics in patients with T2D.
Research type
Research Study
Full title
A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients with Type 2 Diabetes
IRAS ID
287405
Contact name
Oliver Rider
Contact email
Sponsor organisation
Imbria Pharmaceuticals, Inc.
Eudract number
2020-003280-26
Duration of Study in the UK
2 years, 7 months, 1 days
Research summary
Diabetic cardiomyopathy is a disorder of the heart muscle in people with diabetes. Several types of disorders including diabetic cardiomyopathy changes the way heart utilise the energy that results in an inefficient heart with impaired function. This eventually can lead to the inability of the heart to circulate blood through the body effectively and cause heart failure.
In this study, the sponsor, Imbria Pharmaceuticals Inc., plans to investigate a novel drug, IMB-1018972. IMB-1018972 is designed to enhance the efficiency and function of the heart with the aim to reduce heart failure. This study is designed specifically to treat patients with the study drug for a short period of time to evaluate its potential to positively influence the efficiency and function of the heart.
The study will be conducted in 2-stages. Stage 1 will be conducted to define the optimal time frame for evaluating cardiac response to study drug that will be administered to patients. Stage 2 will be conducted in a separate cohort of patients with the aim of evaluating the relationship of the study drug dose on efficiency and function of the heart.
This study will be conducted in only one site in the United Kingdom. Approximately 36 patients above 18 years at screening will be enrolled in the study. The maximum length of the participation in the study will be 20 weeks for stage 1 and 32 weeks for stage 2 of the study.
REC name
London - Hampstead Research Ethics Committee
REC reference
20/LO/1120
Date of REC Opinion
9 Nov 2020
REC opinion
Further Information Favourable Opinion